EU clears BMS’ Orencia for methotrexate-naive RA patients
The European Commission has expanded the approved indications for Bristol-Myers Squibb’s biologic Orencia, now allowing its use in patients with highly active and progressive rheumatoid arthritis who have not been previously treated with methotrexate.
Read More
